8-K: 60 Degrees Pharma Prepares FDA Babesiosis Trial Analysis

60 Degrees Pharmaceuticals is preparing a statistical analysis plan for an interim review of its severe babesiosis trial, with potential for early reporting or sample size adjustments.

Summary

• 60 Degrees Pharmaceuticals, Inc. has prepared a Statistical Analysis Plan (SAP) for an interim analysis of its clinical trial for tafenoquine in severe babesiosis patients.
• The interim analysis will occur by October 30, 2026, or after 24 of the 33 planned patients have been randomized and followed for at least 50 days.
• The analysis will assess time to sustained clinical resolution (TTSCR) and time to molecular cure (TTMC).
• If conditional power for either endpoint is at least 80%, a log-rank test will be performed, and a one-sided statistical significance of 0.02137 or less for TTSCR could lead to early study reporting.
• If conditional power is between 50% and 80%, a sample size reassessment will occur, with a potential increase of up to 33 additional patients (66 total).
• The results will be presented to the Data Safety Monitoring Board (DSMB) for recommendations.
• As of July 7, 2026, 23 patients were enrolled in the study.
• The company intends to apply for a National Priority Review Voucher if trial outcomes support a supplementary New Drug Application (sNDA) submission to the FDA before the end of Q1 2028.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive development, as it outlines a clear, structured approach to advancing a critical clinical trial, though success is contingent on future results and regulatory interactions.

Positives

• The company is actively progressing its clinical trial for tafenoquine in severe babesiosis.
• A clear plan for interim analysis and potential early reporting is in place.
• The trial has a defined pathway for sample size reassessment if needed, with a cap to manage costs.
• The company is aiming for a potential National Priority Review Voucher, indicating a belief in the drug's potential impact.

Negatives

• The trial is still in its early stages, with only 23 out of 33 patients enrolled as of July 7, 2026.
• The possibility of needing a sample size reassessment and additional patients could lead to increased costs and extended timelines.

Risks

• The outcome of the clinical development and interactions with regulatory authorities are subject to risks and uncertainties.
• Actual results could differ materially from those anticipated due to various factors, including market conditions.
• The success of the trial and potential sNDA submission are not guaranteed.

Future Outlook

The company intends to submit an application for a Commissioners National Priority Review Voucher if the outcome of any interim and/or final analysis of the randomized, placebo-controlled trial of tafenoquine in patients hospitalized with severe babesiosis supports moving forward with a supplementary New Drug Application (sNDA) submission to the FDA before the end of the first quarter of 2028. These expectations are forward-looking and subject to risks and uncertainties.

Management Comments

• The Company is providing this disclosure to inform investors regarding its current development and regulatory plans.
• The Company's expectations regarding the trial, any future sNDA submission, and any potential voucher application are forward-looking statements and are subject to risks and uncertainties, including the outcome of clinical development, interactions with regulatory authorities, and other factors that could cause actual results to differ materially from those anticipated.

Industry Context

StockSavvy.ai notes that the preparation of a detailed Statistical Analysis Plan (SAP) for an interim analysis is a standard and crucial step in advancing clinical trials, particularly for novel therapeutics targeting serious infectious diseases like babesiosis. The potential for early reporting or sample size adjustments reflects a proactive approach to trial management and resource allocation, common in the pharmaceutical industry.

Stakeholder Impact

• Shareholders: The progress in the clinical trial and potential for a Priority Review Voucher could impact future company valuation and stock performance.
• Patients: The trial aims to provide a new treatment option for severe babesiosis, a serious and potentially life-threatening condition.
• Regulatory Authorities (FDA): The company is engaging with the FDA through the preparation of trial plans and potential future submissions.

Next Steps

• Perform interim analysis by October 30, 2026, or after 24 patients are randomized and followed for 50 days.
• Present interim analysis results to the DSMB for recommendation.
• Potentially perform sample size reassessment if conditional power is between 50% and 80%.
• Potentially submit an sNDA to the FDA before the end of Q1 2028 if trial outcomes support it.
• Apply for a National Priority Review Voucher if sNDA submission is supported.

Key Dates

Recommendation

The filing provides an update on clinical trial progress and regulatory planning, which is important for the company's future prospects. However, it does not contain definitive results or financial performance data that would warrant a strong buy or sell recommendation at this stage. Investors should await further clinical data and regulatory feedback.

Keywords

60 Degrees Pharmaceuticals, 8-K, Tafenoquine, Babesiosis, Clinical Trial, FDA, Statistical Analysis Plan, Interim Analysis, Priority Review Voucher, sNDA, Severe Babesiosis